- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07940049
CovaRisk: Validating a Digital Tool for Ovarian Cancer Risk Assessment and Referral (CovaRisk)
Bridging Diagnosis and Decision-Making: Retrospective Validation of CovaRisk for Ovarian Malignancy Risk Stratification and Referral Triage
Ovarian cancer is frequently diagnosed at an advanced stage, while its early symptoms are often nonspecific . In women presenting with an adnexal mass, clinicians must integrate clinical symptoms, menopausal status, tumour markers, ultrasound findings, cross-sectional imaging, and hereditary risk when deciding whether a patient requires urgent gynaecologic oncology referral, specialist review, additional imaging, or conservative follow-up . Existing validated tools address individual components of this pathway, but these tools and guideline recommendations are distributed across different resources .
Studieöversikt
Status
Detaljerad beskrivning
CovaRisk is an application-based clinical decision support tool designed to integrate many diagnostic elements into a stepwise assessment . It combines symptom criteria, age-adjusted CA-125 interpretation, HE4/ROMA, Risk of Malignancy Index (RMI), IOTA Simple Rules, O-RADS ultrasound and MRI classification, selected tumour markers, and hereditary risk information. The tool provides a transparent triage category and guideline-based next steps while directing users to established specialist tools where appropriate. CovaRisk is intended to support, rather than replace, clinical judgement and validated specialist models .This study aims to evaluate the diagnostic accuracy of CovaRisk version 1.0 for identifying ovarian malignancy, including borderline tumours, using final histopathology as the reference standard, and to compare its performance with the Risk of Malignancy Index and O-RADS ultrasound classification in the same cohort .This study will be a single-centre retrospective diagnostic accuracy study of women aged 18 years or older who underwent surgery for an adnexal mass and have final histopathology available. Preoperative information will be entered into the frozen CovaRisk version 1.0 without access to the postoperative histopathology result . CovaRisk classification will be compared with final histology as the reference standard. Diagnostic performance will be assessed using sensitivity, specificity, predictive values, likelihood ratios, receiver operating characteristic curves and area under the curve . CovaRisk will also be compared with RMI and O-RADS ultrasound in the same cohort .The study will provide an objective assessment of whether CovaRisk can accurately identify ovarian malignancy in a real-world hospital population. The findings will guide refinement of the tool and determine whether it is appropriate to proceed to subsequent usability testing and prospective validation.Innovation CovaRisk does not introduce a new biomarker or imaging sign; its innovation lies in integration and implementation. Validated tools currently address separate stages of the diagnostic pathway: CA-125 and age-based triage in primary care , ultrasound characterisation of adnexal masses , standardised imaging risk stratification, and hereditary breast and ovarian cancer risk estimation . To our knowledge, CovaRisk is the first tool to integrate symptom-based, laboratory, imaging and hereditary risk assessment for suspected ovarian cancer into a single, transparent, guideline-based triage pathway , and this study will be the first to validate such an integrated tool in a Saudi population.
In addition to measuring diagnostic accuracy, comparison of CovaRisk recommendations with the pathways actually followed will provide an audit of adherence to guideline-based referral and genetic counselling , information that single-score calculators do not provide. These features are consistent with the recognised role of clinical decision support systems in standardising care and reducing unwarranted variation in clinical decision-making .
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: AHMED KAMALELDIN ATTIA, ASCOCIATE PROFESSOR
- Telefonnummer: +966573667477
- E-post: dr.ahmed.attia2021@gmail.com
Studera Kontakt Backup
- Namn: Mohamed Hassan Mohamed, Assistant Professor
- Telefonnummer: +966573667609
- E-post: M_hassan@med.suez.edu.eg
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Women aged 18 years or older who underwent surgery for an adnexal mass at King Faisal Specialist Hospital & Research Centre, Madinah, Saudi Arabia, between January 2021 and December 2025, and who have final histopathology available. Consecutive eligible cases are identified from operating theatre records and the institutional histopathology database. Included records contain sufficient preoperative information, at least a preoperative ultrasound report or a CA-125 result. Women with previous ovarian cancer are excluded. Data are extracted retrospectively from existing medical records; no participants are recruited or contacted.
Beskrivning
Inclusion Criteria:
- Women aged 18 years or older.
- Surgical treatment for an adnexal mass at the host institution during the defined retrospective study period.
- Availability of final histopathology.
- Availability of sufficient preoperative clinical information, including at least a preoperative ultrasound report and CA-125 result, according to the study eligibility definition
Exclusion Criteria:
-
Previous ovarian cancer.
- Absence of both a preoperative ultrasound report and CA-125 result.
- Records in which the relevant preoperative information cannot be reliably established.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: RETROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Retrospective Adnexal Mass Diagnostic Cohort
A single retrospective cohort of women aged 18 years or older who underwent surgical treatment for an adnexal mass at King Faisal Specialist Hospital & Research Centre, Madinah. Preoperative clinical, laboratory, imaging, and hereditary risk data are entered into the CovaRisk version 1.0 tool (blinded to final outcomes), and its diagnostic performance is evaluated against final histopathology as the reference standard, alongside comparative assessments using the Risk of Malignancy Index (RMI) and O-RADS ultrasound classification |
CovaRisk does not introduce a new biomarker or imaging sign; its innovation lies in integration and implementation. Validated tools currently address separate stages of the diagnostic pathway: CA-125 and age-based triage in primary care , ultrasound characterization of adnexal masses , standardized imaging risk stratification , and hereditary breast and ovarian cancer risk estimation . To our knowledge, CovaRisk is the first tool to integrate symptom-based, laboratory, imaging and hereditary risk assessment for suspected ovarian cancer into a single, transparent, guideline-based triage pathway , and this study will be the first to validate such an integrated tool in a Saudi population. In addition to measuring diagnostic accuracy, comparison of CovaRisk recommendations with the pathways actually followed will provide an audit of adherence to guideline-based referral and genetic counselling , information that single-score calculators do not provide.
Andra namn:
|
|
Arm 1: CovaRisk - Diagnostic classification using the CovaRisk version 1.0 tool. Arm 2: Risk of M
This is a retrospective diagnostic accuracy study. These are paired diagnostic assessment methods applied to the same patients, not separate groups receiving different interventions. |
CovaRisk does not introduce a new biomarker or imaging sign; its innovation lies in integration and implementation. Validated tools currently address separate stages of the diagnostic pathway: CA-125 and age-based triage in primary care , ultrasound characterization of adnexal masses , standardized imaging risk stratification , and hereditary breast and ovarian cancer risk estimation . To our knowledge, CovaRisk is the first tool to integrate symptom-based, laboratory, imaging and hereditary risk assessment for suspected ovarian cancer into a single, transparent, guideline-based triage pathway , and this study will be the first to validate such an integrated tool in a Saudi population. In addition to measuring diagnostic accuracy, comparison of CovaRisk recommendations with the pathways actually followed will provide an audit of adherence to guideline-based referral and genetic counselling , information that single-score calculators do not provide.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Sensitivity of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy, Including Borderline Tumors, Against Final Histopathology
Tidsram: Single retrospective record review of surgeries performed January 2021 to December 2025
|
Proportion of women with a histologically confirmed malignant or borderline ovarian tumour who are classified as high-risk by CovaRisk v1.0. CovaRisk is applied to preoperative data already recorded in medical records, without knowledge of the histopathology result. Reported as a percentage with 95% confidence interval. |
Single retrospective record review of surgeries performed January 2021 to December 2025
|
|
Specificity of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy Against Final Histopathology
Tidsram: Single retrospective record review of surgeries performed January 2021 to December 2025
|
•Proportion of women with benign final histopathology who are classified as not high-risk (intermediate, low or information-only) by CovaRisk v1.0. Reported as a percentage with 95% confidence interval. |
Single retrospective record review of surgeries performed January 2021 to December 2025
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Positive Predictive Value of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy
Tidsram: Single retrospective record review of surgeries performed January 2021 to December 2025.
|
Proportion of women classified as high-risk by CovaRisk v1.0 who have malignant or borderline final histopathology, with 95% confidence interval. Unit: percentage of participants |
Single retrospective record review of surgeries performed January 2021 to December 2025.
|
|
Negative Predictive Value of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy
Tidsram: Single retrospective record review of surgeries performed January 2021 to December 2025
|
Proportion of women not classified as high-risk by CovaRisk v1.0 who have benign final histopathology, with 95% confidence interval. Unit: percentage of participants |
Single retrospective record review of surgeries performed January 2021 to December 2025
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Publikationer och användbara länkar
Allmänna publikationer
- Timmerman D, Planchamp F, Bourne T, Landolfo C, du Bois A, Chiva L, Cibula D, Concin N, Fischerova D, Froyman W, Gallardo Madueno G, Lemley B, Loft A, Mereu L, Morice P, Querleu D, Testa AC, Vergote I, Vandecaveye V, Scambia G, Fotopoulou C. ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. Int J Gynecol Cancer. 2021 Jul;31(7):961-982. doi: 10.1136/ijgc-2021-002565. Epub 2021 Jun 10.
- Sadowski EA, Thomassin-Naggara I, Rockall A, Maturen KE, Forstner R, Jha P, Nougaret S, Siegelman ES, Reinhold C. O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee. Radiology. 2022 Apr;303(1):35-47. doi: 10.1148/radiol.204371. Epub 2022 Jan 18.
- American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Gynecology. Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstet Gynecol. 2016 Nov;128(5):e210-e226. doi: 10.1097/AOG.0000000000001768.
- Royal College of Obstetricians and Gynaecologists. The management of ovarian cysts in postmenopausal women. Green-top Guideline No. 34. London: RCOG; 2016
- Royal College of Obstetricians and Gynaecologists. Management of suspected ovarian masses in premenopausal women. Green-top Guideline No. 62. London: RCOG; 2011.
- National Collaborating Centre for Cancer (UK). Suspected Cancer: Recognition and Referral. London: National Institute for Health and Care Excellence (NICE); 2015 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK304993/
- Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29.
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Sjukdomar i det endokrina systemet
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Genitala sjukdomar, kvinnor
- Neoplasmer i endokrina körtel
- Ovariella sjukdomar
- Adnexala sjukdomar
- Genitala neoplasmer, hona
- Gonadal sjukdomar
- Ovariella neoplasmer
Andra studie-ID-nummer
- Alrayan National Colleges
- ALrayan National Colleges (Annan identifierare: ALRAYAN FACULTY OF MEDICINE)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
The document primarily notes that research data will be stored securely on password-protected institutional systems and accessible only to authorized members of the research team in compliance with data-protection requirements.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .